DGX · Quest Diagnostics Inc

Track DGX — free

$230.97 +0.16 (+0.07%) At close · Oct 9

S&P 500 member Russell 1000 member Rebalance outlook locked

Market Cap

$25.49B

110.37M

Volume · Oct 9 775.46K Avg daily vol (3M) 1.04M

Up next

Next earnings call

Oct 23, 2026 Est · unconfirmed · in 2 wks

Latest filing: 10-Q

filed Jul 23, 2026

Q2 2026 earnings call transcript

call held Jul 23, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

$11.56B

Trailing 12 months

Net income (TTM)

$1.06B

Trailing 12 months

Revenue growth YoY

+10.2%

Year over year

Operating margin

14.1%

Trailing 12 months

P / E (TTM)

24.5

Trailing earnings · reciprocal yield 4.1%

FCF yield

5.3%

TTM · current market cap

Return on invested capital

10.0%

Trailing 12 months

Net cash

−$5.02B

Latest balance sheet

Dividend yield

1.5%

Trailing 12 months

Shares change YoY

-0.9%

Year over year · fewer shares

Price change (1Y)

+27.3%

Trailing year

Short interest

3.1%

Latest settlement · 2.7 days to cover

View all 115 metrics

Equibles Rating

blended score · not investment advice

Overall

Buy

SellHoldBuy

Technical Neutral Momentum Very Strong Sentiment Neutral Fundamentals Excellent Quant / Vol Very Low

Market backdrop VIX 14.8 · calm Equity put/call 0.56

Technical

price trend

Neutral

50 / 200-day cross No cross

Price vs 200-day avg +11%

above

Price vs 50-day avg −3%

below

RSI (14) 44

neutral

MACD trend Negative

52-week position 78%

mid-range

Momentum

relative strength

Very Strong

1-month return −2%

trailing

6-month return +18%

trailing

YTD return +33%

this year

Relative strength +8%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $237 › 200d $207 — 50d above 200d

Institutional flow Distributing

50 of 1,116 funds reported for Sep 30 · net -85.7K sh shares · +6 new

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

3.10% of float · ▼ -5.1% MoM · 2.7 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

1,116 holders — near 3-yr high, broad support

Squeeze score 46

elevated · 0–100

Fundamentals

Excellent

Revenue growth +12%

Y/Y

Gross margin 33%

expanding

EPS growth +14%

Y/Y

Free cash flow $1.4B

Valuation P/E 24.5

below peers

Buyback $1.3B

remaining

Balance sheet $5.3B

net debt

Quant / Vol

risk profile

Very Low

Volatility 24%

annualized · 1-yr

Max drawdown −12%

past year

ATR 2.2%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Beat or met 6 of last 8

Latest guidance · from the 8-K filed Jul 23, 2026

Net revenues · Full year 2026 $11.95B – $12.05B

prior FY $11.04B midpoint +8.7% Y/Y

Reported diluted EPS · Full year 2026 $9.97 – $10.17

prior FY $8.75 midpoint +15.1% Y/Y

Adjusted diluted EPS · Full year 2026 $11.05 – $11.25

Guided vs delivered · last 8 settled

Net revenues Full Year 2024

guided $9.5B – $9.58B

guided $9.5B – $9.58B $9.87B Beat +3.5%

Reported diluted EPS Full Year 2024

guided $7.57 – $7.77

guided $7.57 – $7.77 $7.69 In line

Reported diluted EPS Full Year 2023

guided $7.61 – $7.71

guided $7.61 – $7.71 $7.49 Miss −2.2%

Net revenues Full Year 2023

guided $8.93B – $9.08B

guided $8.93B – $9.08B $9.25B Beat +2.7%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral

1 · 4 · 1

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+11% Bullish

Price vs 50-day avg

−3% Neutral

RSI (14)

44 Neutral

MACD trend

Negative Bearish

52-week position

78% Neutral

Market signals — smart money & positioning

Bullish · 2 of 6

Trend (MA cross) No cross

50d $237 › 200d $207 — 50d above 200d

Institutional flow Distributing

50 of 1,116 funds reported for Sep 30 · net -85.7K sh shares · +6 new

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

3.10% of float · ▼ -5.1% MoM · 2.7 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

1,116 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $173 Now $231 · 78% Range high $247

vs 200-day avg +11% vs 50-day avg -3%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
DIS revenues	$2.98B	Three Months Ended June 30, 2026 filing	+10.3%

Organic requisition volume change	13%	Three Months Ended June 30, 2026 filing	—
Requisition volume change	13.1%	Three Months Ended June 30, 2026 filing	—

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Diagnostics & Research — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
DGX Quest Diagnostics Inc this stock	$25.49B	+33.1%	+11.8%	24.5	3.1%
TMO Thermo Fisher Scientific Inc.	$243.30B	+13.6%	+14.5%	35.4	1.5%
DHR Danaher Corp /De/	$154.52B	-4.0%	+8.5%	39.0	1.3%
NTRA Natera, Inc.	$57.76B	+74.9%	-2.8%	—	4.4%
A Agilent Technologies, Inc.	$48.08B	+25.3%	+6.4%	33.6	1.9%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Reducing

Holders

1,119

% held: 95.5%
Reported: 50 of 1,116
Top holder: BlackRock, Inc.

Held Float

View

Held by Funds

Fund positions

863

View

Short & Settlement

Short Interest Falling

Shares short

3.4M

Days to cover: 2.7d
Change: -183.0K sh

View

Short Volume

Short vol %

61%

As of: Oct 9, 2026

Short Total

View

Fails to Deliver

FTD shares

Value: $3.1K
As of: Sep 10, 2026

View

Off-Exchange

Off-exchange %

46.5%

Week of: Sep 7, 2026

Off-exch Lit

View

Smart Money

Congressional Trades Buy

Member

Alan Armstrong

Amount: $1.0K–$15.0K
Traded: Mar 30, 2026

View

Financials

Revenue (FY)

$11.0B

Net income (FY): $992.0M
EPS diluted: $8.75

View

Buybacks

Remaining

$1.3B

View

Filings

SEC Filings

Latest

8-K

Filed: Oct 6, 2026
This year: 13

View

Proposed Sales

Value

$2.4M

Shares: 10.0K
Filed: Sep 1, 2026

View

Earnings & Events

Webcasts

Last webcast

Jul 23, 2026

View

Investor Relations

Performance

	5D	20D	120D	MTD	YTD
DGX	-1.0%	-1.7%	+17.7%	-0.9%	+33.1%
SPY	+1.2%	+1.9%	+9.9%	+2.1%	+14.2%
vs SPY	-2.2%	-3.6%	+7.8%	-3.0%	+18.9%

Capital returns

Latest dividend

$0.86 / share · ex Oct 6, 2026

Raised 7.5%

Paid (TTM)

$3.38 / share · 4 payouts

Dividend yield (TTM, derived)

1.46%

Buyback program · as of Jun 30, 2026

Authorized

—

Spent (derived)

—

Remaining

$1.30B

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1022079 CUSIP 74834L100 13F (30d) 59 filings 55 filers Visit website Investor relations

DGX · Quest Diagnostics Inc

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance

Capital returns